All data are available without restriction in GitHub: <https://github.com/ELELAB/CAncer-bioMarker-Prediction-Pipeline-CAMPP>.

Introduction {#sec001}
============

The availability of sensitive and specific biomarkers for disease diagnosis, prognosis, and monitoring, is an attractive alternative to many of the current methods in use. The presence and levels of certain tissue-derived molecular markers can help distinguish subtypes in heterogeneous diseases such as cancer \[[@pcbi.1007665.ref001],[@pcbi.1007665.ref002]\]. Biomarkers may also be predictive of patient outcome and responsiveness to treatment \[[@pcbi.1007665.ref003],[@pcbi.1007665.ref004]\]. Alas, pinpointing robust cancer biomarkers may be a challenging endeavor. In a review from 2014, Yotsukura and Mamitsuka \[[@pcbi.1007665.ref005]\] showed that out of 7720 publications on biomarkers usage, only 407 of these were patented, and none had obtained FDA approval \[[@pcbi.1007665.ref005]\]. One of the main limitations of biomarker research often relates to small sample size, yielding over-fitted and unreproducible results \[[@pcbi.1007665.ref006],[@pcbi.1007665.ref007]\]. Other pitfalls include a lack of standardized data curation \[[@pcbi.1007665.ref008]\], inappropriate statistical analysis, and lack of validation \[[@pcbi.1007665.ref006],[@pcbi.1007665.ref009],[@pcbi.1007665.ref010]\]. Evaluation of marker specificity and sensitivity is pivotal as most cancer biomarkers have high false-positive rates since a range of non-cancerous events may cause changes in levels of specific biomolecules. Despite these limitations, macromolecular markers remain a promising strategy for diagnosis and subtyping of cancer, as well as other diseases. With the advancements in the field of high throughput data and the increased attention to data normalization and statistical modeling, some drawbacks of biomarker mining may be overcome in the foreseeable future \[[@pcbi.1007665.ref011]\].

Central to the identification of novel disease markers is the bioinformatic analysis of high throughput biological data \[[@pcbi.1007665.ref012]--[@pcbi.1007665.ref016]\]. By applying different statistical tests and machine learning approaches, researchers can go from large datasets with quantitative measurements to a few biomolecules of interest \[[@pcbi.1007665.ref017]--[@pcbi.1007665.ref021]\]. Ideally, biomarker studies of the same disease should be reasonably comparable; however, discrepancies of results are not at all uncommon. While some of these differences arise from variances in study design and experimental procedures, a significant proportion is due to alternating and sometimes inappropriate data normalization and bioinformatic analysis pipeline \[[@pcbi.1007665.ref022]--[@pcbi.1007665.ref024]\]. Standardizing the framework for the detection of biomarker candidates both in the wet lab \[[@pcbi.1007665.ref025]\], as well as the dry lab, should enable researchers to more directly compare results across different studies and starting materials \[[@pcbi.1007665.ref024],[@pcbi.1007665.ref026]\].

We here illustrate The CAncer bioMarker Prediction Pipeline (CAMPP), which is an R-based command-line wrapper for the analysis of high throughput data. The intention behind CAMPP is to provide bioinformatic software-users with a standardized way of screening for potential disease markers, and other biomolecules of interest, prior to potential experimental validation. We have aimed for a pipeline that is intuitive and well-documented, as is good practice \[[@pcbi.1007665.ref027]\].

Design and implementation {#sec002}
=========================

Requirements {#sec003}
------------

The main prerequisite for CAMPP is R and Rstudio. Furthermore, Macbook users must have Xcode installed \[<https://developer.apple.com/xcode/>\], while windows users must ensure they have some equivalent of command-line tools.

Currently, CAMPP is a command-line tool run using Rscript, which is automatically acquired when installing R and Rstudio (most likely path; */usr/local/bin/Rscript)*. Minimum requirements; *R version 3*.*5*.*1* and *Rstudio version 1*.*1*.*463*.

Set-up and package stability {#sec004}
----------------------------

The first time the pipeline is run, all R-packages and dependencies are automatically checked and installed. For installation, a default CRAN mirror is employed; however, this may easily be changed to better fit user location (<https://cran.r-project.org/mirrors.html>).

*Renv*: As updates of R-packages are regular, there is a chance that the code will break, and we therefore also provide the user with the option to use an R-package "freeze", in the form of a *renv* \[[@pcbi.1007665.ref028]\]. To use the *renv* packages, the user must run CAMPP with the argument flag, *-e*, set to "stable".

The CAMPPFunctions.R contains custom functions sourced by the CAMPP.R script (main script), and, as such, these two scripts must be located in the same working directory.

CAMPP may be used to perform a variety of analyses, including preliminary data management, summarized in [Table 1](#pcbi.1007665.t001){ref-type="table"} and [Fig 1A](#pcbi.1007665.g001){ref-type="fig"} below. As the analyses with CAMPP are standardized, the pipeline accepts a range of biological datasets from different high throughput sequencing platforms.

![**A.** Diagram depicting the different types of methodologies and analyses employed by the CAncer bioMarker Prediction Pipeline (CAMPP). **B.** Diagram depicting the structure of CAMPP output, with folders and subfolders organized by analyses.](pcbi.1007665.g001){#pcbi.1007665.g001}

10.1371/journal.pcbi.1007665.t001

###### Table summarizing preliminary data management and analyses implemented in CAMPP, along with specific methods and underlying R-packages.

![](pcbi.1007665.t001){#pcbi.1007665.t001g}

                                               Type                                                                                                                 R-package
  -------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  **Preliminary Data Management**                                                                                                                                   
  Missing Value Imputation                     K-nearest neighbor                                                                                                   impute \[[@pcbi.1007665.ref030]\]
  Data Normalization                           Normalize between arrays and mean/median centering                                                                   R Base
  Data Transformation                          log2, log10, logit, voom                                                                                             R Base
  Data Distribution Fitting                    Normal, Weibull, Lognormal, Gamma, Poisson, Binomial                                                                 fitdistrplus \[[@pcbi.1007665.ref035]\]
  **Analysis**                                                                                                                                                      
  K-means Clustering                           Hartigan and Wong algorithm, BIC                                                                                     R Base, mclust \[[@pcbi.1007665.ref036]\]
  Differential Expression/Abundance Analysis   Empirical Bayes Framework for Linear Models                                                                          edgeR \[[@pcbi.1007665.ref032]\], limma \[[@pcbi.1007665.ref037]\], sva \[[@pcbi.1007665.ref041]\]
  LASSO / Elastic-Net Regression               Group LASSO/EN---multinomial                                                                                         glmnet \[[@pcbi.1007665.ref042]\], pROC \[[@pcbi.1007665.ref043]\]
  Co-Expression/Abundance Correlations         WGCNA, Pearson, Spearman                                                                                             WGCNA \[[@pcbi.1007665.ref044]\], R Base
  Survival Analysis                            Cox Proportional Hazard Regression                                                                                   survcomp \[[@pcbi.1007665.ref045]\]
  Interaction Networks                         STRING \[[@pcbi.1007665.ref047]\], miRTarBase \[[@pcbi.1007665.ref048]\] and TargetScan \[[@pcbi.1007665.ref049]\]   multiMiR \[[@pcbi.1007665.ref050]\]

User input {#sec005}
----------

The user must provide; (I) a matrix with expression/abundance values, (II) a metadata file which should contain at least two columns, a column with sample ids, matching the column names in the expression/abundance file and a column specifying which group (disease state, treatment etc.) a given sample belongs to and (III) the user has to specify which type (variant) of data is provided for analysis, current options are; a*rray*, *seq*, *ms or other*.

Value imputation and pseudocounts {#sec006}
---------------------------------

If the input data contains missing expression values, these will automatically be imputed using Local Least Squares Imputation, LLSI \[[@pcbi.1007665.ref029]\], or K-Nearest Neighbor Imputation, KNNI \[[@pcbi.1007665.ref030]\]. The default method is LLSI, as this type of imputation has been shown to perform better on expression data \[[@pcbi.1007665.ref031]\].

Data normalization, filtering, and transformation {#sec007}
-------------------------------------------------

For RNA sequencing data (*seq*) variables with low counts over all groups (tissue, treatment) are filtered out, library sizes are scaled (weighted trimmed mean of M-values, TMM) \[[@pcbi.1007665.ref032]\], and data are voom-transformed \[[@pcbi.1007665.ref017]\]. For microarray data, (*array*) data are log2-transformed and either quantile normalized \[[@pcbi.1007665.ref032],[@pcbi.1007665.ref033]\] or standardized using mean or median \[[@pcbi.1007665.ref034]\]. Mass spectrometry data (*ms*), are log-transformed (log2, log10, or logit) and standardized using mean or median \[[@pcbi.1007665.ref034]\].

Preliminary data distributional checks {#sec008}
--------------------------------------

As default, the pipeline utilized the R-package *fitdistrplus* \[[@pcbi.1007665.ref035]\] to generate skewness-kurtosis plots (Cullen and Frey graphs) for ten randomly selected variables. Distributions are fitted to data by maximum likelihood, and parameters of the distribution are estimated with bootstrap-resampling to simulate variability \[[@pcbi.1007665.ref035]\]. In addition to the Cullen and Frey graphs, histograms, quantile-quantile, and probability-probability plots are returned.

Clustering of samples {#sec009}
---------------------

CAMPP will test several of centroids for K-means clustering, the exact number of which will depend on the size of the dataset. After clustering, the R-package *mclust* \[[@pcbi.1007665.ref036]\] is employed to evaluate which number of clusters is "optimal" for the input data, based on the Bayesian Information Criterion (BIC). The pipeline will return an Multidimensional Scaling (MDS) plot depicting the "best" clustering of samples. In addition, CAMPP will output the original metadata file with a column specifying which cluster each sample was assigned to. If desired, the user may re-run CAMPP, using the k-means column for variable selection.

Variable selection with differential expression analysis and elastic-net regression {#sec010}
-----------------------------------------------------------------------------------

Variable selection with CAMPP employs *limma* (linear models for microarray data) for differential expression/abundance analysis (DEA, DAA) \[[@pcbi.1007665.ref037]\]. *Limma* was originally designed for analysis of microarray data and subsequently revised to handle RNA sequencing data. However, this software is very flexible and has recently been shown to also perform very well with quantitative mass spectrometry data \[[@pcbi.1007665.ref038],[@pcbi.1007665.ref039]\]. In addition to being versatile, *limma* has been shown to work exceptionally well on datasets with small sample sizes \[[@pcbi.1007665.ref017],[@pcbi.1007665.ref040]\]. DEA may be performed with correlation for experimental batches and other confounders. Batch-correction is performed by directly incorporating batches into the model design matrix \[[@pcbi.1007665.ref041]\]. Batch correction is achieved by specifying the name of the column in the metadata file, which contains the batch information (with flag *-b*)---see user manual for specifics.

As DEA most often yields a long list of variables, CAMPP also performs Least Absolute Shrinkage and Selection Operator (LASSO) or Elastic Net (EN) regression with *glmnet* \[[@pcbi.1007665.ref042]\].

EN/LASSO may be performed in two ways; (I) the dataset is split into training and testing subsets, k-fold cross-validation is performed on the training dataset, followed by estimation of specificity and sensitivity (area under the curve = AUC) \[[@pcbi.1007665.ref043]\] using the test dataset, or (Il) k-fold cross validation is performed using the full dataset. CAMPP will automatically estimate whether the input dataset is large enough to split. The pipeline will perform regression analysis ten times and output bar-plots of cross-validation errors and AUCs for each run. Results of DEA, LASSO/EN regression, and the overlap between these are output in tables.

Weighted co-expression network analysis {#sec011}
---------------------------------------

CAMPP may be used to perform Spearman correlation analysis, with testing for significance and correction for multiple testing (FDR). The user may perform a Weighted Gene Co-Expression Network Analysis. For this type of analysis, CAMPP relies on the R-package WGCNA \[[@pcbi.1007665.ref044]\]. To reduce the contribution from low correlations, mainly assumed to be noise, the WGCNA software estimates soft thresholding powers for exponentiation. Co-expression analysis will result in a plot of variable clustering, before merging and after merging of modules (modules with \< 25% dissimilarity are merged by default). A heatmap showing the strength of variable co-expression within each module will be generated, if the module contains \< = 100 variables---more than this will yield an unreadable plot. CAMPP will return tabular .txt files, one from each module, with the topmost interconnected variables within a module (default is 25%) and accompanying interconnectivity score plots.

Survival analysis---Pinpointing prognostic biomarkers {#sec012}
-----------------------------------------------------

Users may perform survival analysis with Cox proportional hazard regression \[[@pcbi.1007665.ref045]\] within CAMPP. To run survival analysis, the provided metadata file must contain at least three columns; *age* = age in years at diagnosis, surgery, or entry into trial, *outcome*.*time =* time until the end of follow-up and *outcome* = specifying censuring or death (0 or 1). In addition to age, the user wishes to correct for other potential confounders. The pipeline checks two underlying assumptions of the Cox model before performing survival analysis: (I) a linear relationship of continuous covariates with log hazards, and (II) proportional hazards of categorical and continuous covariates, i.e., constant relative hazard \[[@pcbi.1007665.ref046]\]. If the requirement of linearity is not fulfilled, cubic splines will be added to the covariate(s) in question.

Interaction networks {#sec013}
--------------------

After variable selection, the user may generate protein-protein and/or miRNA-gene interaction networks. If gene expression data are used as input for CAMPP, protein-protein interactions are retrieved from the STRING database \[[@pcbi.1007665.ref047]\], and pairs, where both genes (proteins) are differentially expressed, are extracted. The pipeline can accept a variety of gene identifiers. If miRNA expression data are used as input, then miRNA-gene interaction pairs are retrieved from either miRTarBase (validated targets) \[[@pcbi.1007665.ref048]\], TargetScan (predicted) \[[@pcbi.1007665.ref049]\], or a combination of both \[[@pcbi.1007665.ref050]\]. Mature miRNA identifiers or miRNA accession are allowed as input. If the user has both gene and miRNA expression values from the same sample cohort, both protein-protein and miRNA-gene pairs are retrieved, and the results are combined. In this case, the pipeline will return pairs where the fold changes of gene and miRNA are inverse, one up-regulated and the other down-regulated. Interaction network analysis with CAMPP will result in a tabular .txt file with all extracted interactions, including logFCs, FDRs, and interaction scores. This file may be used for visualization of networks with Cytoscape \[[@pcbi.1007665.ref051]\] or another similar tool. In addition, a plot of the top 100 "strongest" interactions are returned.

Results {#sec014}
=======

Case Study 1 {#sec015}
------------

Analysis of Single-Channel Microarray Data, Variable Selection, WGCNA and, Gene-Gene Interactions.

For the testing of an array dataset, we used mRNA expression data from single-channel microarrays \[[@pcbi.1007665.ref052]\]. The dataset contained 80 breast tumor samples with expression quantified for \~ 15.000 mRNAs. Clinical data included, among other things, information on the classification in breast cancer subtypes. Data were background-corrected for ambient intensities before analysis.

We used CAMPP to perform variable selection. Missing values were imputed, data were log2 transformed and normalized between arrays. Additionally, data were corrected for experimental batches and tumor immune scores. Variables with the ability to separate patient estrogen receptor status (ER+ vs. ER-) were selected with elastic-net (alpha = 0.5) and DEA. For this contrast, patient distribution across the two groups was balanced, and CAMPP divided the data into training and testing sets. Subtype-specific expression profiles were also compared; however, as only nine samples where available for one of the subtypes, elastic-net regression was performed without splitting the dataset. As the lack of a test set increases the chance of overfitting significantly, elastic-net results merely provided support for DEA results.

[Fig 2](#pcbi.1007665.g002){ref-type="fig"} shows an example of the data checks performed with *fitdistrplus* \[[@pcbi.1007665.ref035]\] on a set of n (default is 10) randomly extracted variables from the dataset. The gene used as an example in [Fig 2](#pcbi.1007665.g002){ref-type="fig"} is FAM27E2 (Family With Sequence Similarity 27 Member E2), randomly selected from the ten data check plots. FAM27E2 and the other nine genes tested by random, all displayed approximate normal distributions, indicating that these were appropriate for further analysis (see specifics on this in user manual in the GitHub repository). [Fig 3](#pcbi.1007665.g003){ref-type="fig"} shows the number of up- and down-regulated genes from DEA overlapped with results of elastic-net regression, for the comparison of estrogen receptor status (ER- vs. ER+). [Fig 3](#pcbi.1007665.g003){ref-type="fig"} also contains a MDS plot for data-overview and statistics on cross-validation error and area under the curve (AUCs) for each of the ten elastic-net runs. Lists of DE genes, results of LASSO regression, and all plots may be found in the *GitHub repository (CS1*.*zip)*.

![The output of a CAMPP data check.\
The gene used in this example is FAM27E2, randomly selected from the ten variable check plots. Top panel from the left; Cullen and Frey graph showing skewness and kurtosis of normalized and transformed expression data and histogram with different distribution models overlayed. Lower panel from left, quantile-quantile, and probability-probability plot.](pcbi.1007665.g002){#pcbi.1007665.g002}

![Results of gene selection using DEA and elastic-net regression.\
The dataset contained \~ 15.000 genes and 80 samples, groups used for contrast were estrogen positive (n = 61) vs estrogen negative samples (n = 19). Fig 3A is a multidimensional scaling plot showing the partitioning of samples (based on all genes), colored by estrogen status. Fig 3B shows the overlap of results from elastic-net regression (alpha = 0.5) and differential expression analysis with significance cutoffs logFC \> 1 or \< -1 and FDR \< 0.05. Fig 3C depicts the performance statistics for elastic-net regression, e.g., 10-fold cross-validation errors and area under the curve (AUC) scores for the test set. Elastic-net is run 10 times with different random seeds.](pcbi.1007665.g003){#pcbi.1007665.g003}

As seen from [Fig 3B](#pcbi.1007665.g003){ref-type="fig"}, a total of 147 genes were found to be down-regulated in ER- vs ER+ (up in ER+), while 156 genes were up-regulated in ER- vs. ER+ (down in ER+). Elastic-Net regression resulted in 20 genes, out of which nine overlapped with DEA results. Plots of cross-validation errors and AUCs displayed good convergence, with AUCs ranging between 0.96--1.0. The inspection of the nine genes from the overlap between DEA and elastic-net revealed that two of these were Estrogen Receptor 1 and RAS Like Estrogen Regulated Growth Inhibitor, both up-regulated in the ER+ samples compared to ER- samples, in accordance with expectation \[[@pcbi.1007665.ref053]\]. Two of the genes which were up-regulated in ER-negative samples encoded for solute carriers, known to be associated with more aggressive types of breast cancer \[[@pcbi.1007665.ref054]--[@pcbi.1007665.ref056]\]. The heatmap in [Fig 4](#pcbi.1007665.g004){ref-type="fig"} shows the partitioning of breast tissue samples based on the consensus set of variables from DE analysis and elastic-net regression.

![The heatmap in Fig 4 shows the partitioning breast cancer tissues into estrogen receptor-positive (ER+) samples and estrogen receptor-negative (ER-) samples, based on the consensus set of variables from differential expression analysis and elastic-net regression.\
Green = ER+ samples and Purple = ER- samples. Color scale of heatmap (blue to yellow) denotes log2 fold change.](pcbi.1007665.g004){#pcbi.1007665.g004}

In summary, a total of 290 genes were differentially expressed between subtypes, out of which 20 were also identified by elastic-net regression---in total elastic-net returned 42 genes. The set of 20 consensus genes encompassed many well-known genes with the potential to distinguish subtypes. In addition to three Pam50 genes; ERBB2, ESR1 and FOXA1 \[[@pcbi.1007665.ref057]\], the consensus set included; C1orf64 (ER-related factor, ERRF) which was down-regulated in TNBC, in accordance with literature \[[@pcbi.1007665.ref058],[@pcbi.1007665.ref059]\], CDK12, which was up-regulated in Her2 samples, supported by literature indicating that a total of 71% of Her2-enriched tumors overexpress this gene \[[@pcbi.1007665.ref060]\]. Other genes of interest were CYP2B6 \[[@pcbi.1007665.ref061]\], MYLK3 \[[@pcbi.1007665.ref062]\], and SLURP1 \[[@pcbi.1007665.ref063]\].

We used CAMPP to perform WGCNA. In this example, WGCNA was generated only for the DE genes. [Fig 5](#pcbi.1007665.g005){ref-type="fig"} shows a subset of results from WGCNA with genes DE between breast cancer subtypes. [Fig 5](#pcbi.1007665.g005){ref-type="fig"} sub-Figs; (I) 5A, a module dendrogram, (II) 5B, an example of a module heatmap showing co-expression of genes in one of the small modules, module 2, and (III) 5C, an example of a module interconnectivity plot, for the top 25% (default setting) most interconnected genes in module 2. The six genes returned as the most interconnected in this module were strongly associated with the Her2-enriched BC subtype. These genes included ERBB2 (HER2 itself), GRB7 (a Pam50 classifier gene) and MIEN1, CDK12, PGAP3, and TCAP, all of which are ERBB2 amplicon passenger genes \[[@pcbi.1007665.ref064]--[@pcbi.1007665.ref066]\].

![Results of Weighted Gene Co-expression Network Analysis on dataset of \~ 15.000 genes and 80 samples.\
As the dataset contained more than 5000 variables, WGCNA was performed in a block-wise manner to save computational time, in accordance with the WGCNA reference manual \[[@pcbi.1007665.ref044]\]. Fig 5A shows the module clustering tree for the first block as an example. Fig 5B depicts the co-expression heatmap for the small module 2, in which a set of six genes display highly correlated expression patterns. Fig 5C contains the top 25% (in this case five) most interconnected genes from the small module 2, with module interconnectivity scores.](pcbi.1007665.g005){#pcbi.1007665.g005}

Lastly, to evaluate whether the variables found to partition BC subtypes were predicted to interact, we used the pipeline to generate protein-protein interaction networks. [Fig 6](#pcbi.1007665.g006){ref-type="fig"} shows the top 100 strongest gene-gene interactions based on absolute logFC, and interaction score for the comparison of Her2-enriched vs Luminal A, as an example. Results for comparison of all subtypes pairwise may be found in the *GitHub repository (CS1*.*zip)*. From the plot in [Fig 6](#pcbi.1007665.g006){ref-type="fig"}, the two most interconnected genes in the contrast of Her2-enriched vs Luminal A samples, were ERBB2 and ESR1 (Estrogen Receptor 1). As expected, ERBB2 was highly up-regulated, while ESR1 was down-regulated in this comparison. Collectively, results highlight the utility of the complementary R-frameworks implemented in the CAMPP wrapper.

![Plot showing the top 100 best protein-protein (gene-gene) interaction pairs from the analysis of HER2-enriched vs Luminal A samples.\
Colors denote the log fold change of a gene; yellow = up-regulated and blue = down-regulated. The size of the node shows the absolute log fold change, while the ordering from left to right denotes the degree of node interconnectivity. The width of the arch represents the interaction score from the STRING database.](pcbi.1007665.g006){#pcbi.1007665.g006}

Case Study 2 {#sec016}
------------

Analysis of N-glycans from LC Tandem Mass Spectrometry---Clustering, Tissue-Serum Correlation and, Survival Analysis

For case study 2, we analyzed quantitative N-glycan data from liquid-chromatography tandem mass spectrometry (LC-MS/MS). N-glycan abundances have been quantified from tumor and normal interstitial fluids (TIFs and NIFs). In addition to interstitial fluids, we had paired serum samples, enabling us to perform TIF-serum N-glycan abundance correlation analysis with CAMPP. We have published the results of the in-depth analysis of these data here; \[[@pcbi.1007665.ref067]\]. Before differential abundance analysis, we used the pipeline to perform K-means clustering of the samples. When running K-means with CAMPP, the user may specify labels to add to the MDS plots generated, to see which clinical variables, if any, best explain the observed clusters. From the evaluation of all k-means plot, the best number of clusters appeared to be two, one corresponding to tumor samples and one to normal samples. [S1 Fig](#pcbi.1007665.s001){ref-type="supplementary-material"} shows the two clusters with labels.

After clustering analysis, we performed DAA and elastic-net regression, as described in the section on variable selection and in Case Study 1. Cut-off for FDR \< 0.05 and for elastic-net regression alpha was set to = 0.5. DAA yielded a total of 20 N-glycan groups (12 up-regulated in cancer vs normal and eight down-regulated in cancer vs. normal), while elastic-net returned six N-glycan groups, all encompassed by the DA set---results may be found in the GitHub repository *(i*.*e*., *CS2*.*zip)*. Serum correlation analysis and survival analysis were performed on the set of DE N-glycans. [Fig 7](#pcbi.1007665.g007){ref-type="fig"} shows the results of the correlation analysis with paired N-glycan abundances from TIFs and serum. Three N-glycan groups, GP1, GP37, and GP38 were found to displayed significant correlation scores after correction for multiple testing. [Fig 7A](#pcbi.1007665.g007){ref-type="fig"} shows correlation scores of all tested N-glycans, while 7B shows the individual scatter plots produced for the three significant N-glycan groups. Lastly, Cox proportional hazard regression was performed with correction for age at diagnosis as well as immune scores, as immune infiltration has been shown to be associated with patient response to treatment and survival \[[@pcbi.1007665.ref068]\]. [Fig 8](#pcbi.1007665.g008){ref-type="fig"} shows the hazard ratios for the DA N-glycan groups with confidence intervals. As seen from the figure, one N-glycan group, GP38, was significantly associated with overall survival, e.g., a high level of TIF GP38 was predictive of a poor patient outcome.

![Results of correlation analysis with N-glycan abundances in interstitial fluids and paired serum samples.\
Dataset contained a total of 103 samples (51 normal interstitial fluids and 52 tumor interstitial fluids) with \~70 N-glycan groups (165 N-glycans). Fig 7A shows the correlation scores for differentially abundant N-glycan groups, three of these, GP1, GP37, and GP38 met the requirement for significance (corr \> 0.5 and fdr \< 0.05), y-axis = Spearman correlation coefficient. Fig 7B shows the individual correlation plots for the three significant N-glycan groups, x-axis = tumor interstitial fluid abundance and y-axis = serum abundance.](pcbi.1007665.g007){#pcbi.1007665.g007}

![Results of survival analysis (cox-proportional hazard regression) with correction for patient age at diagnosis and tumor infiltrating lymphocyte status (TILs).\
Survival analysis was run on the set of differentially expressed N-glycan groups. Only one N-glycan, GP38, was significant after correction for multiple testing. Hazard ratios are displayed on a log2 scale with confidence intervals, x-axis = N-glycan groups, and y-axis = log2 hazard ratio.](pcbi.1007665.g008){#pcbi.1007665.g008}

Discussion {#sec017}
==========

The CAMPP pipeline supports different types of analysis and will provide the user with graphics to support results---all plots displayed in this publication were generated with CAMPP with no or very minimal editing. CAMPP is implemented in such a way that a user is able to run the pipeline on their local computer on datasets with up to 300--500 samples and 40.000 variables. As an example of this, the user manual, (<https://github.com/ELELAB/CAncer-bioMarker-Prediction-Pipeline-CAMPP/blob/master/CAMPPManual.pdf>) includes the analysis of breast cancer RNA-seq data from TCGA (416 samples and \~ 32.000 gene transcripts, after filtering). For larger datasets, CAMPP may become slow and memory consuming if WGCNA is performed. In this case, it is advisable to run the pipeline on a server, allocating more cores---[Table 2](#pcbi.1007665.t002){ref-type="table"} shows run time, and memory use by CAMPP applied to datasets of different sizes.

10.1371/journal.pcbi.1007665.t002

###### Table showing run times and memory usage for CAMPP applied to datasets of different sizes.

As the weighted gene co-expression network analysis (WGCNA) and estimation of optimal number of clusters for k-means are by far the slowest and most memory consuming processes, we have provided estimates with and without these two analyses. The \[.\] denotes that a given analysis was not performed on a dataset.

![](pcbi.1007665.t002){#pcbi.1007665.t002g}

                  Type of Data        Biological Type   Number of Samples   Number of Variables   WGCNA Variables            K-means   Interaction Networks   Run Time in Minutes   Memory Usage in GB
  --------------- ------------------- ----------------- ------------------- --------------------- -------------------------- --------- ---------------------- --------------------- --------------------
  **Dataset 1**   Mass Spectrometry   N-glycans         80                  165                   All                        Yes       .                      0,3                   0,6
  **Dataset 2**   Array               mRNA              80                  15000                 .                          .         .                      0,8                   0,8
  **Dataset 2**   Array               mRNA              80                  15000                 Differentially Expressed   Yes       .                      3,3                   1,4
  **Dataset 2**   Array               mRNA              80                  15000                 All                        .         .                      12                    7,8
  **Dataset 2**   Array               mRNA              80                  15000                 All                        Yes       .                      15,5                  7,8
  **Dataset 3**   Array + Array       microRNA + mRNA   80                  15754                 .                          .         Yes                    4                     1,6
  **Dataset 3**   Array + Array       microRNA + mRNA   80                  15754                 Differentially Expressed   Yes       Yes                    5,6                   1,6
  **Dataset 3**   Array + Array       microRNA + mRNA   80                  15754                 All                        .         Yes                    16                    7,8
  **Dataset 4**   Array               mRNA              80                  29274                 .                          .         .                      1,2                   0,9
  **Dataset 4**   Array               mRNA              80                  29274                 Differentially Expressed   Yes       .                      3,8                   1,9
  **Dataset 5**   Sequencing          mRNA              416                 55150                 .                          .         .                      3                     1,5
  **Dataset 5**   Sequencing          mRNA              416                 55150                 Differentially Expressed   .         .                      3,5                   1,4
  **Dataset 5**   Sequencing          mRNA              416                 55150                 Differentially Expressed   Yes       .                      12,8                  2,3

We compared the pipeline to other open-source tools for throughput data analysis, found to have similar functionalities and user demographics. [S1 Table](#pcbi.1007665.s002){ref-type="supplementary-material"} shows a summary of the CAncer bioMarker Prediction Pipeline (CAMPP), alongside a selection of other software \[[@pcbi.1007665.ref069]--[@pcbi.1007665.ref079]\]. As seen from this comparison the strengths of CAMPP lie both in (I) the variety of analysis it can perform, (II) that the pipeline is able to handle different types of quantitative biological data, from different platforms and (III) that it is flexible in terms of modeling co-variates. Also, unlike most of the other tools, CAMPP employs *limma* for DE analysis. One advantage of *limma* is that this software has been shown to perform well even with very small sample sizes \[[@pcbi.1007665.ref017],[@pcbi.1007665.ref040],[@pcbi.1007665.ref080]\], a low power scenario that is not unfamiliar in biomedical research. Lastly, the pipeline is relatively fast to run even with larger gene expression datasets and somewhat robust to different operating systems as it relies on R/Rstudio, which are continuously maintained to follow system updates.

We have tried to ensure that the software is user-friendly to those without much programming experience. However, we aware that this tool requires the user to work in a terminal environment and to have R and command-line tools installed on their computer. As such, this pipeline is targeted towards bioinformatic software users and computational-inclined bio-researchers.

In summary, CAMPP is an R-based command-line tool for downstream analysis of high throughput biological data. CAMPP was developed with the intent to provide the biomedical community with an automated way of screening for biomolecules of interest while ensuring a standardized framework for data normalization and statistical analysis.

Availability and future directions {#sec018}
==================================

The CAncer bioMarker Prediction Pipeline (CAMPP) is open source and may be downloaded from the github repository: <https://github.com/ELELAB/CAncer-bioMarker-Prediction-Pipeline-CAMPP>.

As it may be of interest for CAMPP users to understand in detail, how the underlying code and functions work, our plan for the future is to include an R-markdown code run-though. This way the code may more easily be copied and modified and improved, hopefully for the benefit of the computational biology community and for the pipeline itself, as code suggestions and revisions are welcome.

Supporting information {#sec019}
======================

###### Multidimensional scaling plot.

Plot showing the result of k-means clustering with k = 2. The two clusters support the presumed difference between N-glycan abundances in normal interstitial fluid vs tumor interstitial fluid samples.

(PDF)

###### 

Click here for additional data file.

###### Comparison of the CAncer bioMarker Prediction Pipeline (CAMPP) with other tools for high-throughput data analysis.

This table includes a detailed comparison of the analyses and tools implemented in CAMPP with respect to other bioinformatic resources available.

(XLSX)

###### 

Click here for additional data file.

The authors would like to thank Vendela Rissler and Emiliano Maiani for testing CAMPP and for helping us with debugging. The calculations described in this paper were performed using the DeiC National Life Science Supercomputer at DTU.
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1 Aug 2019

Dear Dr Papaleo,

Thanks for your Presubmission Inquiry regarding your manuscript \'CAncer bioMarker Prediction Pipeline (CAMPP) - A standardised framework for the analysis of quantitative biological data.\'. Although we think that your study is interesting, we do not think it provides a significant enough advance or broad enough appeal to our readership for us to consider publishing in PLOS Computational Biology. However, we very much appreciate your wish to present your work in an open-access publication and therefore want to alert you to an alternative that you may find attractive. PLOS ONE is a unique swift, high-volume system for the publication of peer-reviewed research from any scientific discipline. PLOS ONE aims to exploit the full potential of the web to make the most of every piece of research; if you would like to submit your work to PLOS ONE, please visit [www.plosone.org](http://www.plosone.org) and submit your work online.

Editor\'s specific comments:

Please excuse the delayed response on your presubmission inquiry. Unfortunately, the software does not provide the strength of advance in functionality that we are seeking in manuscripts for the Software section of PLOS Computational Biology. Thanks for considering PLOS and I wish you well on your journey to communicate this work to the scientific community.

Thanks for considering PLOS Computational Biology, and good luck with your work.

Yours sincerely,

Aaron E. Darling

Software Editor

PLOS Computational Biology

10.1371/journal.pcbi.1007665.r002
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Click here for additional data file.
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1 Oct 2019

Dear Dr Papaleo,

Thank you very much for submitting your manuscript \'CAncer bioMarker Prediction Pipeline (CAMPP) - A standardised framework for the analysis of quantitative biological data.\' for review by PLOS Computational Biology. Your manuscript has been fully evaluated by the PLOS Computational Biology editorial team and in this case also by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the manuscript as it currently stands. While your manuscript cannot be accepted in its present form, we are willing to consider a revised version in which the issues raised by the reviewers have been adequately addressed. We cannot, of course, promise publication at that time.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

Your revisions should address the specific points made by each reviewer. Please return the revised version within the next 60 days. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by email at <ploscompbiol@plos.org>. Revised manuscripts received beyond 60 days may require evaluation and peer review similar to that applied to newly submitted manuscripts.

In addition, when you are ready to resubmit, please be prepared to provide the following:

\(1\) A detailed list of your responses to the review comments and the changes you have made in the manuscript. We require a file of this nature before your manuscript is passed back to the editors.

\(2\) A copy of your manuscript with the changes highlighted (encouraged). We encourage authors, if possible to show clearly where changes have been made to their manuscript e.g. by highlighting text.

\(3\) A striking still image to accompany your article (optional). If the image is judged to be suitable by the editors, it may be featured on our website and might be chosen as the issue image for that month. These square, high-quality images should be accompanied by a short caption. Please note as well that there should be no copyright restrictions on the use of the image, so that it can be published under the Open-Access license and be subject only to appropriate attribution.

Before you resubmit your manuscript, please consult our Submission Checklist to ensure your manuscript is formatted correctly for PLOS Computational Biology: <http://www.ploscompbiol.org/static/checklist.action>. Some key points to remember are:

\- Figures uploaded separately as TIFF or EPS files (if you wish, your figures may remain in your main manuscript file in addition).

\- Supporting Information uploaded as separate files, titled Dataset, Figure, Table, Text, Protocol, Audio, or Video.

\- Funding information in the \'Financial Disclosure\' box in the online system.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com> PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see [here](http://journals.plos.org/ploscompbiol/s/submission-guidelines#loc-materials-and-methods). 

We are sorry that we cannot be more positive about your manuscript at this stage, but if you have any concerns or questions, please do not hesitate to contact us.

Sincerely,

Mihaela Pertea

Software Editor

PLOS Computational Biology

Mihaela Pertea

Software Editor

PLOS Computational Biology

A link appears below if there are any accompanying review attachments. If you believe any reviews to be missing, please contact <ploscompbiol@plos.org> immediately:

\[LINK\]

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The authors present a new data analysis pipeline for commonly used omics data (gene expression microarray and RNA-seq data, as well as mass-spec data). The pipeline uses well tested and commonly used methods in the field (Limma, glmnet, etc.), which is positive. The statistical assumptions and approaches appear sound, and the pipeline produces biologically meaningful output when applied to a real microarray dataset (ER+/- negative identifies ESR1 as top differentially expressed gene). My key main concern relates to the usability and the target user group of the pipeline. See below for detailed comments:

\#\# Major issues

\#\#\# Target user group

The authors write that "this pipeline is targeted towards bioinformatic software users and computational-inclined bio-researchers." My main concern is that computational-inclined researchers will prefer to piece together their own pipeline (even if using exactly the same components as CAMPP) to control and test key parameters in the analysis. Instead, I think the pipeline could be very useful for researchers that have limited computational know-how. However, this group of people may likely need a much more thorough and user-friendly explanation of the output than what CAMPP currently provides. From a quick inspection of the output, CAMPP generally provides very technical plots that will be difficult to interpret for the average user with limited statistical expertise.

\#\#\# RNA-seq data

Most current gene expression data is generated using RNA-seq. It is unfortunate that the authors do not provide an example and validation using this type of data. The authors could for example compare ER+/- RNA-seq data from TCGA and compare with their microarray results. This would also allow the authors to demonstrate the scalability of their software (e.g. running on 300-500 samples and 40.000 variables).

\#\#\# Minor

\#\#\# Data distributional checks

The pipeline runs a set of distributional checks on 10 randomly selected variables. This analysis is summarised in a set of plots for each variable. A key problem here is that this information is not summarised and presented well to the user. Assuming that the average user has limited statistical expertise, it is not clear how they should act on this information. Furthermore, it is not clear how the outcome of these checks affect the downstream analysis pipeline.

\#\# Compute requirements

Information on computational/hardware requirements should be more specific. How much RAM is needed to run 300-500 samples and 40.000 variables? What's the runtime? Can the software take advantage of multi-core systems?

\#\#\# Batch effects

The authors write that the pipeline can adjust for batch effects, but it is not clear how the user supplies batch information in the input data.

\#\# Comparison with other pipelines, table 2

The information in table 2 is not easy to digest. Firstly, information for CAMPP is not included(?). Secondly, the table is very large (2-pages), so it's not easy to compare pipelines.

Reviewer \#2: Terkelsen et al. present a useful pipeline for the detection of biomarkers from input data matrices such as gene expression or protein abundance values. It covers various aspects of data processing, including normalization and batch effect correction. The tool is available via github and can easily be installed in R. The code is well structured and sufficiently commented. The user manual guides users through installation and usage. It has an open source license and can thus be modified and used freely. It is suitable as a starting place for biomedical researchers familiarizing themselves with biomarker discovery. I have some suggestions for improvements:

CAMPP depends on R packages which tend to change over time. To avoid that CAMPP quickly becomes unusable I strongly suggest one of the following options:

\- build a docker container

\- use the R packrat package to bind CAMPP to a static version of its dependencies

Table 2 is very clunky. Could this be solved with a table that has checkmarks when features are implemented in one of the tools?

Minor:

\- ElasticNet: the parameter alpha for balancing ridge and lasso regression should be adjustable

\- It is not clear to me why all four columns are needed for survival analysis. Age is useful to consider but not strictly necessary to perform survival analysis. Is it used as a confounder?

\- typo: trail -\> trial

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Computational Biology* [data availability policy](http://journals.plos.org/ploscompbiol/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Markus List
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18 Jan 2020

Dear Prof. Papaleo,

We are pleased to inform you that your manuscript \'CAncer bioMarker Prediction Pipeline (CAMPP) - A standardized framework for the analysis of quantitative biological data\' has been provisionally accepted for publication in PLOS Computational Biology.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch within two working days with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Computational Biology. 

Best regards,

Mihaela Pertea

Software Editor

PLOS Computational Biology

Mihaela Pertea

Software Editor

PLOS Computational Biology

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer\'s Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer \#1: The authors have addressed all my concerns. I would like to congratulate the authors on a much improved manuscript. Especially the run time information (table 1), the more user friendly table 2, and the references to additional information in the user manual.

Minor point:

Many important details are provided in the user manual, which is great. I would encourage the authors to reference this manual more frequently in the main manuscript text. For example referencing the new RNA-seq analysis of TCGA breast cancer. The authors could for example reference this analysis in the discussion, and comment on whether the analysis results are generally concordant with the microarray analysis (eg1. ESR1 overexpression in ER+/Luminal tumors, and HER2 over expression in HER2+ tumors).

Reviewer \#2: The authors have addressed all of my previous comments.

\*\*\*\*\*\*\*\*\*\*

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the

PLOS Computational Biology

[data availability policy](http://journals.plos.org/ploscompbiol/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?

For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Markus List
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CAncer bioMarker Prediction Pipeline (CAMPP) - A standardized framework for the analysis of quantitative biological data

Dear Dr Papaleo,

I am pleased to inform you that your manuscript has been formally accepted for publication in PLOS Computational Biology. Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out, the early version of your manuscript will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Computational Biology and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Matt Lyles

PLOS Computational Biology \| Carlyle House, Carlyle Road, Cambridge CB4 3DN \| United Kingdom <ploscompbiol@plos.org> \| Phone +44 (0) 1223-442824 \| [ploscompbiol.org](http://ploscompbiol.org) \| \@PLOSCompBiol
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